4.00
price up icon5.15%   0.21
 
loading
전일 마감가:
$3.79
열려 있는:
$3.8
하루 거래량:
691.75K
Relative Volume:
0.87
시가총액:
$168.90M
수익:
$3.64M
순이익/손실:
$-87.37M
주가수익비율:
-0.9153
EPS:
-4.37
순현금흐름:
$-86.46M
1주 성능:
-3.51%
1개월 성능:
+11.62%
6개월 성능:
-66.96%
1년 성능:
-36.54%
1일 변동 폭
Value
$3.72
$4.15
1주일 범위
Value
$3.71
$4.285
52주 변동 폭
Value
$2.10
$14.22

Verastem Inc Stock (VSTM) Company Profile

Name
명칭
Verastem Inc
Name
전화
(781) 292-4200
Name
주소
117 KENDRICK STREET, NEEDHAM, MA
Name
직원
73
Name
트위터
@VerastemOncolog
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
VSTM's Discussions on Twitter

VSTM을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
VSTM 3.99 168.90M 3.64M -87.37M -86.46M -4.37
VRTX 450.44 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.45 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 590.18 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.35 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.90 24.89B 3.30B -501.07M 1.03B 11.54

Verastem Inc Stock (VSTM) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2022-09-07 재개 Alliance Global Partners Buy
2022-04-29 재개 Cantor Fitzgerald Overweight
2022-04-14 개시 RBC Capital Mkts Outperform
2022-03-09 개시 Truist Buy
2021-07-01 개시 Alliance Global Partners Buy
2021-05-24 업그레이드 BTIG Research Neutral → Buy
2019-06-20 다운그레이드 BTIG Research Buy → Neutral
2019-05-10 다운그레이드 Raymond James Outperform → Mkt Perform
2018-07-13 개시 BTIG Research Buy
2018-05-02 개시 Seaport Global Securities Buy
2018-03-08 개시 B. Riley FBR, Inc. Buy
2017-09-07 재확인 H.C. Wainwright Buy
2017-04-13 개시 Oppenheimer Outperform
2017-03-24 재확인 H.C. Wainwright Buy
2015-09-29 다운그레이드 Cantor Fitzgerald Buy → Hold
2015-09-29 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2015-09-29 다운그레이드 Jefferies Buy → Hold
2015-09-29 다운그레이드 Raymond James Strong Buy → Outperform
2015-09-28 다운그레이드 Mizuho Buy → Neutral
2015-09-28 다운그레이드 ROTH Capital Buy → Neutral
2015-09-09 개시 Raymond James Strong Buy
2015-05-12 재확인 UBS Buy
2015-04-08 개시 H.C. Wainwright Buy
2015-01-23 재확인 ROTH Capital Buy
2014-07-08 재개 Oppenheimer Perform
2014-02-11 개시 Mizuho Buy
모두보기

Verastem Inc 주식(VSTM)의 최신 뉴스

pulisher
Nov 20, 2024

KRAS Inhibitors Market Report 2034: Epidemiology Data, - openPR

Nov 20, 2024
pulisher
Nov 16, 2024

Data-Based Insights About Verastem Inc (VSTM) - Stocks Register

Nov 16, 2024
pulisher
Nov 15, 2024

OrbiMed Advisors LLC's Strategic Acquisition of Verastem Inc Sha - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Alyeska Investment Group L.P.'s Strategic Acquisition of Veraste - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Nov 15, 2024
pulisher
Nov 15, 2024

Verastem, Inc. (NASDAQ:VSTM) Receives $14.57 Average PT from Analysts - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Verastem's SWOT analysis: oncology firm's stock faces pivotal FDA decision - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Verastem's SWOT analysis: oncology firm's stock faces pivotal FDA decision By Investing.com - Investing.com Canada

Nov 14, 2024
pulisher
Nov 13, 2024

Stonepine Capital Management, LLC Increases Stake in Verastem Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Such Is The Power Of Verastem Inc (NASDAQ: VSTM) - Stocks Register

Nov 13, 2024
pulisher
Nov 09, 2024

Verastem (NASDAQ:VSTM) Stock Rating Lowered by StockNews.com - Defense World

Nov 09, 2024
pulisher
Nov 07, 2024

Verastem CEO Paterson sells $3,118 in common stock - Investing.com

Nov 07, 2024
pulisher
Nov 07, 2024

Verastem CEO Paterson sells $3,118 in common stock By Investing.com - Investing.com UK

Nov 07, 2024
pulisher
Nov 07, 2024

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates - BioSpace

Nov 07, 2024
pulisher
Nov 07, 2024

Verastem: Q3 Earnings Snapshot - The Washington Post

Nov 07, 2024
pulisher
Nov 06, 2024

Verastem, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024
pulisher
Nov 04, 2024

Chugai PharmaceuticalVerastem Oncology's Announcement Regarding Avutometinib - Marketscreener.com

Nov 04, 2024
pulisher
Nov 02, 2024

Avutometinib With Defactinib for Recurrent KRAS Mutant LGSOC Completes Rolling New Drug Application - Pharmacy Times

Nov 02, 2024
pulisher
Nov 01, 2024

Verastem Oncology submits NDA for ovarian cancer treatment - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Verastem (FRA:2VSA) Owner Earnings per Share (TTM) : -3.30 (As of Jun. 2024) - GuruFocus.com

Nov 01, 2024
pulisher
Oct 31, 2024

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - StockTitan

Oct 31, 2024
pulisher
Oct 31, 2024

Verastem Oncology to Participate in Upcoming Investor Conferences - BioSpace

Oct 31, 2024
pulisher
Oct 30, 2024

SG Americas Securities LLC Purchases New Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World

Oct 30, 2024
pulisher
Oct 24, 2024

Verastem's SWOT analysis: ovarian cancer drug maker's stock faces pivotal year - Investing.com India

Oct 24, 2024
pulisher
Oct 21, 2024

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Oct 21, 2024
pulisher
Oct 18, 2024

Verastem preps an NDA as the stock struggles - BioWorld Online

Oct 18, 2024
pulisher
Oct 18, 2024

Verastem's (VSTM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

Verastem Holders Endure Difficult Day, Analysts Holding Firm (VSTM) - AskTraders

Oct 18, 2024
pulisher
Oct 17, 2024

Truist keeps $15 target on Verastem amid sell-off By Investing.com - Investing.com UK

Oct 17, 2024
pulisher
Oct 17, 2024

Verastem Advances Cancer Treatment with Promising Trial Results - TipRanks

Oct 17, 2024
pulisher
Oct 17, 2024

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting - StockTitan

Oct 17, 2024
pulisher
Oct 15, 2024

This trade activity should not be overlooked: Verastem Inc (VSTM) - SETE News

Oct 15, 2024
pulisher
Oct 14, 2024

Verastem Inc (VSTM) stock: A year of ups and downs - US Post News

Oct 14, 2024
pulisher
Oct 10, 2024

Verastem CFO sells shares worth $17 to cover tax obligations By Investing.com - Investing.com Canada

Oct 10, 2024
pulisher
Oct 09, 2024

Verastem CFO sells shares worth $17 to cover tax obligations - Investing.com India

Oct 09, 2024
pulisher
Oct 09, 2024

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting - StockTitan

Oct 09, 2024
pulisher
Oct 07, 2024

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Oct 07, 2024
pulisher
Oct 05, 2024

Verastem whipsaws after updates for cancer drug combo - MSN

Oct 05, 2024
pulisher
Oct 03, 2024

Taking the lead: Verastem Inc (VSTM) - SETE News

Oct 03, 2024
pulisher
Oct 02, 2024

Guggenheim’s latest rating for VSTM stock - Knox Daily

Oct 02, 2024
pulisher
Oct 02, 2024

Verastem Inc’s results are impressive - US Post News

Oct 02, 2024
pulisher
Oct 01, 2024

Nantahala Capital Management LLC Purchases Shares of 400,000 Verastem, Inc. (NASDAQ:VSTM) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Verastem Inc (VSTM) Stock: A Year of Decreases and Increases - The InvestChronicle

Oct 01, 2024
pulisher
Oct 01, 2024

Guggenheim Initiates Coverage of Verastem (VSTM) with Buy Recommendation - Nasdaq

Oct 01, 2024
pulisher
Oct 01, 2024

Nantahala Capital Management LLC Takes Position in Verastem, Inc. (NASDAQ:VSTM) - MarketBeat

Oct 01, 2024

Verastem Inc (VSTM) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
자본화:     |  볼륨(24시간):